{ "schemaVersion": "deck-intelligence.v1", "id": "019de076-b3a4-71cc-8183-985590ab9557", "slug": "2fc842fd1dad3dbfa44767764fb3543f", "title": "MaxCyte | Investor Presentation Deck | 21 slides", "subtitle": "MaxCyte · 2024-01", "author": "MaxCyte", "date": "2024-01-01 00:00:00", "pageCount": 21, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de076-b3a4-71cc-8183-985590ab9557", "slug": "2fc842fd1dad3dbfa44767764fb3543f", "title": "MaxCyte | Investor Presentation Deck | 21 slides", "rawTitle": "MaxCyte | Investor Presentation Deck | 21 slides", "authorId": "maxcyte", "authorName": "MaxCyte", "authorDisplay": "MaxCyte", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2024-01__maxcyte__investor-pres__2fc842fd.pdf", "sourceUrl": "https://www.slidebook.io/company/maxcyte/presentation/2fc842fd1dad3dbfa44767764fb3543f/", "sourceDate": "2024-01-15 00:00:00", "presentationDate": "2024-01-01 00:00:00", "ingestedAt": "2026-04-30 22:16:08.969209+00", "status": "ready", "pageCount": 21, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "medical-devices", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2024-01__maxcyte__investor-pres__2fc842fd", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 21, "pagesIndexed": 21, "pagesWithImages": 21, "pagesWithMetadata": 21, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 113, "chartCount": 8, "metricSlides": 0, "toolMatches": 7, "documentToolMatches": 0, "frameworkMatches": 11, "arcMatches": 1, "beatMatches": 5, "loopMatches": 3, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with sections on problem, solution, traction, business model, and ask.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:42:20.131115+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Problem", "beatId": "5e779fca-b3fc-47b1-84f6-7724896679e4", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The problem statement is presented on page 5.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 6, "name": "Solution", "beatId": "184d686a-4e9e-4fe1-852b-7a5b688bd3bb", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is presented on page 6.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Traction", "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": null, "evidence": "Traction is showcased from pages 7-14.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 17, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 16, "name": "Business Model", "beatId": "e4f7a46b-9042-439c-bd19-663ca53403ca", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "The business model is explained on pages 16-17.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 21, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 21, "name": "The Ask", "beatId": "099b16d1-851c-4c93-9cff-a4e90fb2b444", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": { "name": "The Ask", "slug": "sequoia-pitch-the-ask", "status": "active", "canonId": "019dd9b8-24f3-72bf-940a-74d06fd9396b", "version": 1, "description": null }, "evidence": "The ask is presented on page 21.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 6, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "77b85c35-fbe8-46b0-acc0-1343f8c27f84", "evidence": "The problem statement and solution sections imply the cost of inaction.", "position": 0, "objective": "What are the consequences of not addressing cell engineering challenges?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.340364+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 14, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887", "evidence": "The traction section highlights the benefits of partnering with MaxCyte.", "position": 1, "objective": "What are the benefits of partnering with MaxCyte?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.374959+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 21, "from": 20, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "41f99638-2ab7-4bc5-8e96-09ca064b209b", "evidence": "The closing ask section implies that now is the right time to invest.", "position": 2, "objective": "Why is now the right time to invest in MaxCyte?", "confidence": 0.5, "extraction": { "at": "2026-07-16 22:42:20.409062+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "ba4576b3-cff2-45ab-ad46-7fdadabfac13", "evidence": "MaxCyte Corporate Presentation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:36.374284+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bd25519d-cab6-4539-a532-edc9758648d7", "evidence": "Enables delivery of almost any molecule into almost any cell type; Leads the industry in performance; Extensive product portfolio; ~25% 5-Year CAGR; ~89% gross margins", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:36.504053+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "99723d60-1c3c-418e-8d7e-b3710492bfe0", "evidence": "list/comparison: Next-generation cell therapy programs have become increasingly complex requiring multiple edits vs Flow Electroporation technology facilitates multiplex and sequential engineering without the payload", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:36.63331+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a256c9e5-35e2-49d6-b7f8-6a608a808eb5", "evidence": "Cumulative Potential Pre-CML Milestones", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:41.801002+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a40501df-d9ed-4d9b-8ff5-4fdeeaa4dcfe", "evidence": "list/bullet: 2023 Achievements: Five SPL partnerships, CFO appointment, ESG report, First therapy approval", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:41:36.215617+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Call to action", "slug": "call-to-action", "status": "active", "bestFor": null, "canonId": "019dd9e1-4bbb-702a-9ead-82daf188bb7c", "version": 1, "bodyDocId": null, "description": "Explicit prescription of what the audience should do next.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "70fabed5-30d3-4d95-9115-66db08d19ede", "evidence": "paragraph/paragraph: ir@maxcyte.com", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:36.339785+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Storytelling: the closing ask", "slug": "closing-ask", "status": "active", "bestFor": null, "canonId": "019df269-24e0-70ab-8dd9-983832c1c665", "version": 1, "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d", "description": "The single most important slide in the deck — after the cover. The final", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "372698dd-bc93-49c3-b5de-6b83ccc982ba", "evidence": "title/headline: Thank you! Any questions?", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:36.297743+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "cfc3b704-bb63-4498-bc7b-09f340eee211", "evidence": "Chronological progression of company milestones", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:10:08.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "timeline" }, { "matchId": "e69e5271-fd1f-4af5-a151-31b2d7649da3", "evidence": "Maps specific industry challenges to corresponding product solutions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:10:08.58+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "before-after-bridge" }, { "matchId": "6a802b44-0f13-4a45-b155-8b1d9415bdb3", "evidence": "Central node connected to peripheral nodes representing supporting pillars.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:10:12.716+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "hub-spoke" }, { "matchId": "73496a1d-0ed2-4a26-b5dc-2039e994a3d7", "evidence": "The chart displays partner milestones across a chronological axis from 2017 to 2024.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:10:09.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "timeline" }, { "matchId": "25ed0b4f-62ce-4f7f-bfa5-10a464eb996e", "evidence": "Maps revenue stages to clinical development phases", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:10:14.016+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "customer-journey-map" }, { "matchId": "dbd7dfb9-ca59-48ae-9667-311a2ee078df", "evidence": "Sequential waves representing future growth phases", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:10:10.018+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "timeline" }, { "matchId": "6f320bdd-322d-47c6-a042-1ab56b8a6ee2", "evidence": "Explicitly stated as 'Razor/Razor Blade Economics' in the revenue model flow.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:10:13.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "frameworkName": "razor-razor-blade" }, { "matchId": "0c21e232-3423-4116-b9f6-09712452bf5a", "evidence": "Explicitly mentioned in the text as the economic model for both segments.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:10:09.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "razor-razor-blade" }, { "matchId": "9f64ba25-40fa-4429-bdd3-d2c01600b03f", "evidence": "Contrasts traditional lengthy process with accelerated VLx-enabled approach.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "before-after-framing" }, { "matchId": "0fe9f999-5131-4390-9966-5451d950b69d", "evidence": "Comparison of traditional vs new workflow timelines", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 11:10:14.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "before-after-framing" }, { "matchId": "ecd6a47c-e535-42c0-aa3d-8416a749baba", "evidence": "The slide presents a chronological summary of achievements across two distinct time periods.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:10:10.026+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "timeline" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/p5toIHQ1SSzI074n0BFFPIoNKnloJ5BIlICDgqZTQnE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yZmM4NDJmZDFkYWQzZGJmYTQ0NzY3NzY0ZmIzNTQzZi9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 4, "textChars": 245, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:07.954+00", "seconds": 2.656, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/1", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-1", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.4, "x": 0.075, "y": 0.9 }, "kind": "disclaimer", "text": "MaxCyte expert ATx STx GTx are registered trademarks of MaxCyte, Inc. in the U.S.A. VLx is a trademark of MaxCyte, Inc.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:07.954+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2980ea3-be40-4299-a536-c6a161546554", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.25, "x": 0.075, "y": 0.725 }, "kind": "image", "text": "MaxCyte", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:07.954+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb97eca3-7950-4f60-8a36-1c2c4f0554f1", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.075, "y": 0.4 }, "kind": "paragraph", "text": "MaxCyte Corporate Presentation\nNASDAQ: MXCT • LSE: MXCT\nJanuary 2024", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:07.954+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9739cd66-a32e-4c3b-a82a-75f5b8ffcb7c", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.65, "x": 0.075, "y": 0.175 }, "kind": "title", "text": "Driving the Next Generation of Cell-Based Therapies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:07.954+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d794e1e1-0817-4cba-8a4b-81ef9b41fecc", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "ba4576b3-cff2-45ab-ad46-7fdadabfac13", "evidence": "MaxCyte Corporate Presentation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:36.374284+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/wDWA81cidVuKxmFjbWxK4-z2ptf1e2n2W_ltlFddBCw/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yZmM4NDJmZDFkYWQzZGJmYTQ0NzY3NzY0ZmIzNTQzZi9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/_h-QktkLYwFyuujijKaftL0Lm_lYbikqwZGIl2bOVFQ/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yZmM4NDJmZDFkYWQzZGJmYTQ0NzY3NzY0ZmIzNTQzZi9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/xXT-etG2Tey40jK8LM0_HLbDcMDCeIz5kL-W_Zx4u1U/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8yZmM4NDJmZDFkYWQzZGJmYTQ0NzY3NzY0ZmIzNTQzZi9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 20, "componentCount": 3, "textChars": 202, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:07.342+00", "seconds": 2.042, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/2", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-2", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.93, "x": 0.035, "y": 0.24 }, "kind": "disclaimer", "text": "The content of this document (the \"Presentation\") has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 (\"FSMA\"), as amended...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:07.342+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a25506c1-6ed6-45fc-8635-e30305b5a162", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.156, "x": 0.808, "y": 0.058 }, "kind": "image", "text": "MaxCyte", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:07.342+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "426acb40-9fdb-4ae3-9c5e-2e42a1bf1775", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.16, "x": 0.035, "y": 0.075 }, "kind": "title", "text": "Disclaimer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:07.342+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "113e8052-a7de-40e0-866d-a9fde86bbc19", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "The slide uses a three-column layout to summarize technology, market leadership, and business model.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 89, "componentCount": 9, "textChars": 839, "nDataPoints": 7, "notes": "The slide uses a three-column layout to summarize technology, market leadership, and business model.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:09.059+00", "seconds": 3.75, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/3", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-3", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.16, "x": 0.808, "y": 0.045 }, "kind": "image", "text": "MaxCyte", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2932c290-68f6-4858-a32a-15699fff8127", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.03, "y": 0.2 }, "kind": "list", "text": "With 600+ platforms in place, our proprietary technology unlocks the significant potential of advanced therapeutics", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7b9f52c9-2823-4e5b-9b0b-b3a56b53650e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.67, "y": 0.2 }, "kind": "list", "text": "Innovative business model focused on value creation and shared partnership success", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8825ae0e-b506-4d1b-803b-3a5476a1ec4e", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.3, "x": 0.03, "y": 0.45 }, "kind": "list", "text": "Enables delivery of almost any molecule into almost any cell type; Leads the industry in performance; Extensive product portfolio; ~25% 5-Year CAGR; ~89% gross margins", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "970423ba-3153-4128-a8c3-7f8ce6063a89", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.35, "y": 0.2 }, "kind": "list", "text": "Leading the growing next-generation cell therapy market and capitalizing on rising demand for non-viral engineering approaches", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9b1ba298-0fd9-4bc5-a55e-5a0ba2ac0c50", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.3, "x": 0.35, "y": 0.45 }, "kind": "list", "text": "20+ years of expertise; 30+ field sales; Significant collaborations; FDA Master File; Used in 45+ clinical trials", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b3384363-a153-4a2a-964f-76ee26ec5266", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.3, "x": 0.67, "y": 0.45 }, "kind": "list", "text": "Allows MaxCyte to participate in value created; 24 SPL partnerships; ~$2B in potential milestone payments; Focused on long-term diverse portfolio", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e2e6d9f9-eb67-4336-9f5a-18af803ad705", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.67, "y": 0.9 }, "kind": "source-note", "text": "*As of December 31, 2022", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b8fed0e-34dd-46a5-80c3-8065facddafb", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "A Leading Provider of Cell-Engineering Platform Technologies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88efcee9-8639-4d55-89ef-9323c33f88ab", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "bd25519d-cab6-4539-a532-edc9758648d7", "evidence": "Enables delivery of almost any molecule into almost any cell type; Leads the industry in performance; Extensive product portfolio; ~25% 5-Year CAGR; ~89% gross margins", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:36.504053+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "evidence", "title": "The slide uses a dual-track timeline (Cell Therapy and Drug Discovery) to show company evolution.", "function": "show_traction", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 5, "textChars": 232, "nDataPoints": 3, "notes": "The slide uses a dual-track timeline (Cell Therapy and Drug Discovery) to show company evolution.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:08.319+00", "seconds": 2.991, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/4", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-4", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.85, "x": 0.1, "y": 0.2 }, "kind": "chart", "text": "Corporate timeline from 1999 to 2023", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a43f69d4-60a9-4899-a3b9-42f303546aeb", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.16, "x": 0.808, "y": 0.05 }, "kind": "image", "text": "MaxCyte logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "117d3207-42aa-4d21-bdd3-206742e11452", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.14, "y": 0.18 }, "kind": "list", "text": "24 SPL Partnerships Signed Since 2017; 125 Employees*; 30+ Field Sales and Application Scientists*", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b0b92a5e-fcb5-46f1-a45f-d6f79f9f0d5b", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.15, "x": 0.02, "y": 0.95 }, "kind": "source-note", "text": "*As of December 31, 2022", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36f51ff8-6e7d-47cd-85aa-f5e4ec7a3a3f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "Who We Are - Collaborative, Innovative and Experienced Partner", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d17f5ae7-af6d-4bb3-aef2-3ac3f1c5026a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "cfc3b704-bb63-4498-bc7b-09f340eee211", "evidence": "Chronological progression of company milestones", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:10:08.319+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "tension", "title": "Uses a before-after-bridge style framing to connect pain points to product benefits.", "function": "present_solution", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 74, "componentCount": 7, "textChars": 973, "nDataPoints": 0, "notes": "Uses a before-after-bridge style framing to connect pain points to product benefits.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:08.58+00", "seconds": 3.055, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/5", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-5", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.88, "x": 0.06, "y": 0.39 }, "kind": "list", "text": "Next-generation cell therapy programs have become increasingly complex requiring multiple edits vs Flow Electroporation® technology facilitates multiplex and sequential engineering without the payload and capacity limitations of viral approaches", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Comparison list", "slug": "comparison", "status": "active", "canonId": "019de52c-fce7-733e-99d3-030a104727bf", "version": 1, "description": null }, "framework": null }, "subkind": "comparison", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.58+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "014cf9bb-decf-415a-9dee-d0d5026b61fc", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.88, "x": 0.06, "y": 0.65 }, "kind": "list", "text": "Vein-to-vein manufacturing times are high; optimizations needed to deliver medicines to patients faster vs ExPERT™ platform provides industry leading transfection efficiency & cell viability at high scale in 30 minutes or less", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Comparison list", "slug": "comparison", "status": "active", "canonId": "019de52c-fce7-733e-99d3-030a104727bf", "version": 1, "description": null }, "framework": null }, "subkind": "comparison", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.58+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4db2db62-4dbd-4b0c-9884-0efcccb4aacd", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.88, "x": 0.06, "y": 0.26 }, "kind": "list", "text": "Lack of industry standard for process design causes development to be costly and inconsistent across manufacturing runs vs MaxCyte technology allows plug and play processes with rapid optimization delivering reproducible outcomes", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Comparison list", "slug": "comparison", "status": "active", "canonId": "019de52c-fce7-733e-99d3-030a104727bf", "version": 1, "description": null }, "framework": null }, "subkind": "comparison", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.58+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a81fe808-b872-43fd-a0c9-1197816866ed", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.88, "x": 0.06, "y": 0.52 }, "kind": "list", "text": "Regulatory risk increases with new unknowns (donor cells, next-gen approaches, new indications) vs FDA Master File can be referenced in regulatory filings to accelerate and de-risk regulatory review", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Comparison list", "slug": "comparison", "status": "active", "canonId": "019de52c-fce7-733e-99d3-030a104727bf", "version": 1, "description": null }, "framework": null }, "subkind": "comparison", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.58+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6ebc3ea-6298-4017-a9d1-3125d0a4156f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "ExPERT™ Platform Addresses Industry Challenges", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.58+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31bf1da2-9dcb-4be5-9d59-99bbc32b5913", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.15, "x": 0.06, "y": 0.18 }, "kind": "title", "text": "Challenges", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.58+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a970da5b-70af-4314-b3e4-9349f7cff18c", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.25, "x": 0.47, "y": 0.18 }, "kind": "title", "text": "MaxCyte's Solutions", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.58+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "db217d8f-1a90-4e27-933d-db5bffecc62c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "99723d60-1c3c-418e-8d7e-b3710492bfe0", "evidence": "list/comparison: Next-generation cell therapy programs have become increasingly complex requiring multiple edits vs Flow Electroporation technology facilitates multiplex and sequential engineering without the payload", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:36.63331+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "e69e5271-fd1f-4af5-a151-31b2d7649da3", "evidence": "Maps specific industry challenges to corresponding product solutions.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:10:08.58+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "before-after-bridge" } ], "arcBeats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Problem", "beatId": "5e779fca-b3fc-47b1-84f6-7724896679e4", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The problem statement is presented on page 5.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 6, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "77b85c35-fbe8-46b0-acc0-1343f8c27f84", "evidence": "The problem statement and solution sections imply the cost of inaction.", "position": 0, "objective": "What are the consequences of not addressing cell engineering challenges?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.340364+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "resolution", "title": "The central hub is 'Accelerate Product Development', surrounded by four strategic pillars, each with a corresponding icon.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 4, "textChars": 272, "nDataPoints": 1, "notes": "The central hub is 'Accelerate Product Development', surrounded by four strategic pillars, each with a corresponding icon.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:12.716+00", "seconds": 6.837, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/6", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-6", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.09, "w": 0.07, "x": 0.45, "y": 0.16 }, "kind": "chart", "text": "Small bar chart inside 'Shared Momentum' circle showing growth.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:12.716+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79a88a53-3c2d-4e6d-a359-87c517a379f8", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.85, "x": 0.08, "y": 0.15 }, "kind": "diagram", "text": "Hub-and-spoke diagram showing central goal of accelerating product development supported by four pillars.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:12.716+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c3d307cf-d58d-4c44-a5c2-b318376d827d", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.8, "x": 0.1, "y": 0.3 }, "kind": "image", "text": "Icons representing cell biology, support/personnel, and regulatory documentation.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Icon grid", "slug": "icon-grid", "status": "active", "canonId": "019de52c-fdfe-749d-9990-1db465a3eed4", "version": 1, "description": null }, "framework": null }, "subkind": "icon-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:12.716+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "83e07612-b43e-4ee8-a22f-18570d7d916a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "Partnering with MaxCyte", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:12.716+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a7da56e9-595b-4be2-af1c-e3cfb3b75f32", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "6a802b44-0f13-4a45-b155-8b1d9415bdb3", "evidence": "Central node connected to peripheral nodes representing supporting pillars.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:10:12.716+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "hub-spoke" } ], "arcBeats": [ { "to": 6, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 6, "name": "Solution", "beatId": "184d686a-4e9e-4fe1-852b-7a5b688bd3bb", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is presented on page 6.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 6, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "77b85c35-fbe8-46b0-acc0-1343f8c27f84", "evidence": "The problem statement and solution sections imply the cost of inaction.", "position": 0, "objective": "What are the consequences of not addressing cell engineering challenges?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.340364+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "evidence", "title": "The slide uses a process flow diagram to show the funnel from potential partnerships to active clinical programs.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 288, "nDataPoints": 5, "notes": "The slide uses a process flow diagram to show the funnel from potential partnerships to active clinical programs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:08.268+00", "seconds": 2.387, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/7", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-7", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "diagram", "text": "75+ Potential SPL Partnerships; 24 SPL Partnerships signed; 125+ Programs; 16 Programs currently active", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "829e0077-b063-4d50-83cd-6ea56e730bdb", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.65 }, "kind": "image", "text": "Partner logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "205a39d1-0a05-497c-98e4-8f98af1d8380", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.5 }, "kind": "source-note", "text": "**Number of gene-modified ex-vivo cell therapy companies using non-viral delivery. *Updated as of December 31, 2022", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a64224bd-78e8-45a8-a227-cfb5d9e50911", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.68, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "MaxCyte: Leading Partner for Complex Cellular Engineering", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1a392a26-a669-425a-91ff-eb672b360cf1", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Traction", "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": null, "evidence": "Traction is showcased from pages 7-14.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887", "evidence": "The traction section highlights the benefits of partnering with MaxCyte.", "position": 1, "objective": "What are the benefits of partnering with MaxCyte?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.374959+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "evidence", "title": "The chart shows a cumulative growth trend of partner milestones over time, with logos placed in vertical columns representing years.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 5, "textChars": 433, "nDataPoints": 1, "notes": "The chart shows a cumulative growth trend of partner milestones over time, with logos placed in vertical columns representing years.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:09.307+00", "seconds": 3.422, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/8", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-8", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.5, "x": 0.46, "y": 0.14 }, "kind": "chart", "text": "Cumulative Potential Pre-CML Milestones", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fb659d4f-ec28-4524-a629-399fc8889efc", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.84 }, "kind": "disclaimer", "text": "**Casebia/CRISPR's SPL partnership... Graph is provided for illustrative purposes only.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "786fa270-7820-4ae6-8b06-4c8df7582e94", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.45, "x": 0.48, "y": 0.25 }, "kind": "image", "text": "Partner logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee6cc811-7e16-4eab-8868-23e26fb754e7", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.35, "x": 0.1, "y": 0.18 }, "kind": "list", "text": "Licensing deals include significant development milestones and high-value participation in future commercial success of partners. Potential value of pre-commercial milestones from SPLs: ~$2B. Sales-based payments. Recurring revenues. Milestone revenue is highest growth.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "defff335-eef1-41bf-8e0d-d3bb5c55fe36", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "Value Creation from SPLs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "843ea6ee-54d2-49b6-9e85-cdd039da6c92", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a256c9e5-35e2-49d6-b7f8-6a608a808eb5", "evidence": "Cumulative Potential Pre-CML Milestones", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:41.801002+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "73496a1d-0ed2-4a26-b5dc-2039e994a3d7", "evidence": "The chart displays partner milestones across a chronological axis from 2017 to 2024.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:10:09.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "timeline" } ], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Traction", "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": null, "evidence": "Traction is showcased from pages 7-14.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887", "evidence": "The traction section highlights the benefits of partnering with MaxCyte.", "position": 1, "objective": "What are the benefits of partnering with MaxCyte?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.374959+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "setup", "title": "Uses a stacked area chart to represent revenue components (instruments, milestones, sales-based payments) over time.", "function": "present_framework", "rawType": "revenue_buildup", "block": null, "metadata": { "slideType": "revenue_buildup", "slideTypeCanon": { "name": "Revenue buildup", "slug": "revenue_buildup", "status": "active", "canonId": "019de52d-0acd-70b8-a81d-62d89840409b", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 5, "textChars": 346, "nDataPoints": 0, "notes": "Uses a stacked area chart to represent revenue components (instruments, milestones, sales-based payments) over time.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:14.016+00", "seconds": 8.054, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/9", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-9", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.55, "x": 0.16, "y": 0.2 }, "kind": "chart", "text": "Stacked area chart showing revenue growth over time", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked area chart", "slug": "area-stacked", "status": "active", "canonId": "019de52c-ffb1-75fa-a614-76782f418cf1", "version": 1, "description": null }, "framework": null }, "subkind": "area-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.016+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff4ebcd8-57f2-4ef4-9a15-8397d794acd0", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.16, "x": 0.808, "y": 0.05 }, "kind": "image", "text": "MaxCyte", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.016+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0238356f-b8d2-4913-937e-5719e1666a80", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.75, "y": 0.33 }, "kind": "legend", "text": "Cell Therapy Partner Program Value Schematic: Instruments and Processing Assemblies, Milestones, Sales-Based Payments", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.016+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0167c27a-c6f1-4c21-a09c-2aee277be882", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.6, "x": 0.1, "y": 0.2 }, "kind": "list", "text": "Early Clinical (Years 1-3), Mid-late Clinical (Years 3-5+), Approval (Year 5+), Commercial Phase", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.016+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7947deab-9374-44ba-8fe7-09178ddf73fd", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.5, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "Example: Typical Single-Product Revenues from a Representative License Deal", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.016+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6a5ea9f4-e216-4976-8bda-498f638f2673", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "25ed0b4f-62ce-4f7f-bfa5-10a464eb996e", "evidence": "Maps revenue stages to clinical development phases", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:10:14.016+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "customer-journey-map" } ], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Traction", "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": null, "evidence": "Traction is showcased from pages 7-14.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887", "evidence": "The traction section highlights the benefits of partnering with MaxCyte.", "position": 1, "objective": "What are the benefits of partnering with MaxCyte?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.374959+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "evidence", "title": "The slide uses two donut charts to visualize the distribution of milestone events across IND, Pre-Pivotal, and Pivotal or Later phases.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 6, "textChars": 394, "nDataPoints": 1, "notes": "The slide uses two donut charts to visualize the distribution of milestone events across IND, Pre-Pivotal, and Pivotal or Later phases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:08.906+00", "seconds": 2.69, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/10", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-10", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.22, "x": 0.44, "y": 0.82 }, "kind": "callout", "text": "50 potential SPL pre-commercial milestone events over the next 3 years", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d5543f89-9ddb-46ab-a3a4-148f49385375", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.28, "x": 0.41, "y": 0.32 }, "kind": "chart", "text": "2023-2025 milestone distribution", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Donut chart", "slug": "donut", "status": "active", "canonId": "019de52d-0006-752c-9528-0fef476b8004", "version": 1, "description": null }, "framework": null }, "subkind": "donut", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "335c6c3f-c843-47e1-8ac4-50130f12fa6d", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.28, "x": 0.11, "y": 0.32 }, "kind": "chart", "text": "2017-2022 milestone distribution", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Donut chart", "slug": "donut", "status": "active", "canonId": "019de52d-0006-752c-9528-0fef476b8004", "version": 1, "description": null }, "framework": null }, "subkind": "donut", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e27e701b-e5b3-4c05-aa51-1bc69abba835", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.35, "x": 0.05, "y": 0.91 }, "kind": "disclaimer", "text": "As of March 2023 / Pre-Pivotal includes Phase 1, Phase 2 and first manufacturing events", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b72f77d4-177e-4263-bdf1-4d06d522de18", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.22, "x": 0.73, "y": 0.31 }, "kind": "list", "text": "Representative SPL Payments: IND (Low to Mid 6-figure), Pre-Pivotal (Low 7-figure), Pivotal or Later (Low to Mid 7-figure)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5824ca7d-86b6-4dd3-b111-d8ea7424ec7c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "MaxCyte Partnership Pre-Commercial Milestone Events", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.906+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a3ffb0a-9507-4ede-b4b4-bcde9b99ef1b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Traction", "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": null, "evidence": "Traction is showcased from pages 7-14.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887", "evidence": "The traction section highlights the benefits of partnering with MaxCyte.", "position": 1, "objective": "What are the benefits of partnering with MaxCyte?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.374959+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "analysis", "title": "The chart uses a stacked bar format to distinguish between pre-commercial and commercial revenue components.", "function": "analyze_data", "rawType": "revenue_buildup", "block": null, "metadata": { "slideType": "revenue_buildup", "slideTypeCanon": { "name": "Revenue buildup", "slug": "revenue_buildup", "status": "active", "canonId": "019de52d-0acd-70b8-a81d-62d89840409b", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 535, "nDataPoints": 6, "notes": "The chart uses a stacked bar format to distinguish between pre-commercial and commercial revenue components.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:09.702+00", "seconds": 3.486, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/11", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-11", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.4, "x": 0.294, "y": 0.33 }, "kind": "chart", "text": "Example Partnerships NPV", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "676b40c0-fac8-49f7-bab3-e6d82f474133", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.04, "y": 0.76 }, "kind": "disclaimer", "text": "*10-year NPV **Weighted based on the expected split of commercial programs in Year 6 (assuming earliest approval); Assumes first 5-years of standard ten-year biotech sales curve", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0332e149-2808-48d2-bfa5-0d37bc9d3b14", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.72, "y": 0.34 }, "kind": "list", "text": "Influencing Factors: Small indications, Conservative commercial milestones, Lower utilization", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86187bc1-8fc0-445c-8e41-c93ea8d95438", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.05, "y": 0.34 }, "kind": "list", "text": "Influencing Factors: Large indications, Instrument & consumables utilization", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "caee2a3e-9668-4c2f-be56-495cfafb15b6", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.24, "x": 0.45, "y": 0.35 }, "kind": "paragraph", "text": "While pre-commercial revenues are comparable, commercial revenues can vary significantly", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ce32d86-9f58-4efb-90ef-6058332ff344", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.65, "x": 0.04, "y": 0.04 }, "kind": "title", "text": "SPL Partnerships Offer Significant Revenue Upside, Particularly in Commercial", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.702+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "392ff4e5-29ed-4ebf-b671-085b191e0739", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Traction", "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": null, "evidence": "Traction is showcased from pages 7-14.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887", "evidence": "The traction section highlights the benefits of partnering with MaxCyte.", "position": 1, "objective": "What are the benefits of partnering with MaxCyte?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.374959+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "resolution", "title": "The slide uses a wave-based metaphor to represent sequential growth phases of partner programs.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 7, "textChars": 890, "nDataPoints": 5, "notes": "The slide uses a wave-based metaphor to represent sequential growth phases of partner programs.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:10.018+00", "seconds": 3.75, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/12", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-12", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.18, "x": 0.59, "y": 0.00175 }, "kind": "list", "text": "Fourth Wave: 20+ Additional Preclinical Partner Programs, Launch 2030+, Indications: Solid Tumors, Autoimmune, Neurodegenerative, Genetic, Lymphoma/Leukemia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.018+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d2838ac-7be7-4900-bc04-8e7020599f76", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.18, "x": 0.21, "y": 0.00175 }, "kind": "list", "text": "Second Wave: 7 Potential Approved Partner Programs, Launch 2025-2027, SPL Partner A Programs, Caribou, Editas, Precision Bio, Vor, Invios, Indications: Lymphoma/Leukemia, Solid Tumors, Sickle Cell, Beta-Thalassemia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.018+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "52868d2f-7c7d-426c-9cb2-5b2f943b4861", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.18, "x": 0.4, "y": 0.00175 }, "kind": "list", "text": "Third Wave: 8 Potential Approved Partner Programs, Launch 2028-2030, Undisclosed, Indications: Solid Tumors, Lymphoma/Leukemia, Multiple Myeloma, Sickle Cell, Beta-Thalassemia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.018+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "59e4b86f-9e89-41e8-8407-74a6d99937cb", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.18, "x": 0.02, "y": 0.00175 }, "kind": "list", "text": "First Wave: 1 Potential Approved Partner Program, Launch 2024, Vertex's Exa-Cel, Sickle Cell Disease, Beta-Thalassemia", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.018+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7cc6c137-bf2f-4fec-abc7-050d1ebb5e78", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.18, "x": 0.78, "y": 0.00175 }, "kind": "list", "text": "Fifth Wave: Additional Licensed Programs and New Partnerships Signed, Launch 2032+", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.018+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c7843289-5ba8-4419-afd9-1a830d00a09e", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.07, "y": 0.92 }, "kind": "source-note", "text": "Source: Evaluate Pharma as of August 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.018+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d57f55fc-4677-4eed-b90d-40c3a65c705d", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.65, "x": 0.02, "y": 0.04 }, "kind": "title", "text": "MaxCyte Partnerships – Near and Long-Term Revenue Potential with Strong Upside in Commercial Opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.018+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d68a1e06-ad62-417b-8130-65aee59f5b55", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "dbd7dfb9-ca59-48ae-9667-311a2ee078df", "evidence": "Sequential waves representing future growth phases", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:10:10.018+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "timeline" } ], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Traction", "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": null, "evidence": "Traction is showcased from pages 7-14.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887", "evidence": "The traction section highlights the benefits of partnering with MaxCyte.", "position": 1, "objective": "What are the benefits of partnering with MaxCyte?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.374959+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "evidence", "title": "The diagram uses concentric circles to represent clinical phases and color-coded dots for cell approaches (Allogeneic vs Autologous).", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 56, "componentCount": 5, "textChars": 405, "nDataPoints": 12, "notes": "The diagram uses concentric circles to represent clinical phases and color-coded dots for cell approaches (Allogeneic vs Autologous).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:08.923+00", "seconds": 2.635, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/13", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-13", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.65, "x": 0.25, "y": 0.15 }, "kind": "diagram", "text": "Concentric circle diagram showing clinical phases (Phase 1, 1/2, Pivotal, Commercial) and cell approaches (Allogeneic, Autologous).", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "other", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "55b4854b-2176-426f-b373-f69782bd6bce", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.11, "y": 0.2 }, "kind": "legend", "text": "Clinical Phase: Phase 1, Phase 1/2, Pivotal, Commercial. Cell Approach: Allogeneic, Autologous.", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e707b906-6da1-4e7c-994e-12e29a6999bd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.04, "y": 0.72 }, "kind": "paragraph", "text": "As of March 2023 / Includes Commercial and Academic Clinical Trials", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a3e28cdd-2a27-417a-8685-523a33674921", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.04, "y": 0.62 }, "kind": "paragraph", "text": "Program received IND clearance but is not yet listed on clinicaltrials.gov", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a86ed80c-6d8c-4cb9-b923-954d0c6df79e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "MaxCyte-Enabled Active Clinical Trials", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:08.923+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "11559b49-d12e-4c1b-a6ca-67c6556cb52e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Traction", "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": null, "evidence": "Traction is showcased from pages 7-14.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887", "evidence": "The traction section highlights the benefits of partnering with MaxCyte.", "position": 1, "objective": "What are the benefits of partnering with MaxCyte?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.374959+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "evidence", "title": "The slide uses a Vitruvian-man style silhouette to represent the breadth of therapeutic applications.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 7, "textChars": 780, "nDataPoints": 1, "notes": "The slide uses a Vitruvian-man style silhouette to represent the breadth of therapeutic applications.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:10.345+00", "seconds": 3.915, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/14", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-14", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.3, "x": 0.68, "y": 0.58 }, "kind": "callout", "text": "First MaxCyte-Enabled Therapy is Approved CASGEVY for Sickle Cell Disease (UK + US) for Beta-Thalassemia (UK) UK MHRA Nov 2023 US FDA Dec 2023", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.345+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "16211b51-97bd-4971-a7ff-5a6db57154d7", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.215, "x": 0.228, "y": 0.298 }, "kind": "image", "text": "Human silhouette graphic", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.345+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d41c9ad-77bd-4064-add5-1ce1d5d60e7e", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "Genetic Diseases: Beta-Thalassemia, Sickle Cell Disease, Chronic Granulomatous Disease (CGD); Solid Tumors: Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Other Solid Tumors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.345+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "09a0b3b2-3e18-4a87-af1c-d1c1445c3af7", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.7, "y": 0.25 }, "kind": "list", "text": "ARCUS, Base-editing (CRISPR), CRISPR, RNA-Based Engineering, TALENS, Zinc Finger Nucleases (ZFNs)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.345+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b18e27e2-9270-4765-bf54-619b12f06029", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.25, "x": 0.45, "y": 0.25 }, "kind": "list", "text": "Infectious Disease: HIV; Hematological Malignancies: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, T Cell Lymphoma", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.345+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e9052438-3f49-4e44-b542-439e954bc638", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.1, "y": 0.75 }, "kind": "metric", "text": "1,000+ Patients in active clinical trials enabled by MaxCyte", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.345+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8d06b651-80d0-4c50-ba21-73412c78cd01", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "MaxCyte Enables Next-Generation Cell Therapies Across a Variety of Diseases", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.345+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "863906c7-a8f9-4525-a0a6-a5d503f72174", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Traction", "beatId": "20c42468-2c81-4751-a1f9-a6ba473e7c5e", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": null, "evidence": "Traction is showcased from pages 7-14.", "position": 2, "isPrimaryArc": true, "parentBeatType": null, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "860b177a-a306-4d07-b9f0-f03de41e9887", "evidence": "The traction section highlights the benefits of partnering with MaxCyte.", "position": 1, "objective": "What are the benefits of partnering with MaxCyte?", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:42:20.374959+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "resolution", "title": "The slide highlights the scalability and versatility of the platform from research to clinical manufacturing.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 4, "textChars": 611, "nDataPoints": 6, "notes": "The slide highlights the scalability and versatility of the platform from research to clinical manufacturing.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:09.201+00", "seconds": 2.715, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/15", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-15", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.55, "x": 0.4, "y": 0.18 }, "kind": "image", "text": "ExPERT Instrument Portfolio (ATx, STx, GTx, VLx)", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.201+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f9026460-e4af-4c79-928d-b3541c98547d", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.35, "x": 0.04, "y": 0.18 }, "kind": "list", "text": "Launched in 2019 based on MaxCyte’s proprietary Flow Electroporation® technology... Leverages the reversible permeability... Universally delivers molecules... Agnostic to cell type... Enables customers to use a single platform... Supported by a robust IP portfolio", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.201+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5f489e18-8406-4dc2-902f-b627f9c1776a", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.55, "x": 0.4, "y": 0.55 }, "kind": "list", "text": "High Performance: >90% transfection, >90% cell viabilities, Computer-controlled. Flexibility: Single buffer, Pre-loaded library. Scalability: 75k to 7M cells, 20B cells in <30m, 200B cells in <30m. High Quality: Sterile, cGMP, FDA Master File.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.201+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dbca3936-a9da-421f-9c9e-e278a83c383f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "The ExPERT™ Platform Enabling Non-Viral Cell Engineering", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.201+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d7d8bece-f972-4aec-9c44-c02659f290ee", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 16, "type": "setup", "title": "The model is explicitly labeled as 'Razor/Razor Blade Economics'.", "function": "present_solution", "rawType": "business_model", "block": null, "metadata": { "slideType": "business_model", "slideTypeCanon": { "name": "Business model", "slug": "business_model", "status": "active", "canonId": "019de52d-0fa6-7104-86d0-e5781f8b8b45", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 6, "textChars": 446, "nDataPoints": 0, "notes": "The model is explicitly labeled as 'Razor/Razor Blade Economics'.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:13.861+00", "seconds": 7.37, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/16", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-16", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.92, "x": 0.036, "y": 0.52 }, "kind": "framework", "text": "Drug Discovery Revenue Model: Instrument sale (ATx/STx) + Single-use disposables (processing assemblies) = Razor/Razor Blade Economics", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:13.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1490366-9bc1-4615-a030-eacdd9571d90", "parentComponentId": null }, { "bbox": { "h": 0.17, "w": 0.41, "x": 0.44, "y": 0.2 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:13.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4fe08d44-4e57-49aa-9608-e2d78376baed", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.15, "x": 0.23, "y": 0.64 }, "kind": "image", "text": "ATx Small/mid-scale RUO", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:13.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "860d4cab-338d-4ace-aaf5-a57c6225ab80", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.15, "x": 0.48, "y": 0.64 }, "kind": "image", "text": "STx Full scale RUO", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:13.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9eb0f6db-d347-4406-8509-fde28935efba", "parentComponentId": null }, { "bbox": { "h": 0.16, "w": 0.375, "x": 0.036, "y": 0.21 }, "kind": "paragraph", "text": "DRUG DISCOVERY & DEVELOPMENT - Cells used to Discover / Produce Drug Products\nKey Applications: Cell-based assays, protein and antibody production, vaccine development\nCustomer base: Large/small biopharma and academic centers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:13.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c31a764-b327-4858-9700-6f1694ef5cfa", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.615, "x": 0.036, "y": 0.09 }, "kind": "title", "text": "MaxCyte Business Model – Drug Discovery Market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:13.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6e9358f-cffd-4699-8681-e905dc1e25cd", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "6f320bdd-322d-47c6-a042-1ab56b8a6ee2", "evidence": "Explicitly stated as 'Razor/Razor Blade Economics' in the revenue model flow.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:10:13.861+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "frameworkName": "razor-razor-blade" } ], "arcBeats": [ { "to": 17, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 16, "name": "Business Model", "beatId": "e4f7a46b-9042-439c-bd19-663ca53403ca", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "The business model is explained on pages 16-17.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 17, "type": "setup", "title": "Uses the 'Razor/Razor Blade' business model framework.", "function": "present_solution", "rawType": "business_model", "block": null, "metadata": { "slideType": "business_model", "slideTypeCanon": { "name": "Business model", "slug": "business_model", "status": "active", "canonId": "019de52d-0fa6-7104-86d0-e5781f8b8b45", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 5, "textChars": 521, "nDataPoints": 0, "notes": "Uses the 'Razor/Razor Blade' business model framework.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:09.92+00", "seconds": 3.238, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/17", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-17", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.9, "x": 0.045, "y": 0.65 }, "kind": "diagram", "text": "SPL Partnership Model: Annual Instrument License Fee (GTx) + Single-use Disposables + Strategic Partnership Terms = Razor/Razor Blade Economics and Share of Therapeutic Economics", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d75d62a-2575-4b42-934a-7cc80533b028", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.9, "x": 0.045, "y": 0.35 }, "kind": "diagram", "text": "Preclinical and Academic Revenue Model: Instrument Sale (ATx/GTx) + Single-use Disposables = Razor/Razor Blade Economics", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b3f109c5-0009-41c8-9488-b0d87af149bf", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.3, "x": 0.22, "y": 0.42 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "67d54b67-6fe3-40ce-8655-3ba550977aca", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.045, "y": 0.17 }, "kind": "paragraph", "text": "CELL THERAPY – Cell itself is the Drug\nKey Applications: Ex-Vivo Engineered Cell Therapies\nCustomer Base: Leading global cell therapy developers and academic translational centers", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "682f0e30-201a-4757-86b2-9b847b0ceeea", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.45, "x": 0.045, "y": 0.075 }, "kind": "title", "text": "MaxCyte Business Model – Cell Therapy Market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "283b45df-27cf-4d8c-82fe-159283f58915", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "0c21e232-3423-4116-b9f6-09712452bf5a", "evidence": "Explicitly mentioned in the text as the economic model for both segments.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:10:09.92+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 17, "frameworkName": "razor-razor-blade" } ], "arcBeats": [ { "to": 17, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 16, "name": "Business Model", "beatId": "e4f7a46b-9042-439c-bd19-663ca53403ca", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": { "name": "Business Model", "slug": "sequoia-pitch-business-model", "status": "active", "canonId": "019dd9b8-22f4-768a-8822-31509f575122", "version": 1, "description": null }, "evidence": "The business model is explained on pages 16-17.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 18, "type": "resolution", "title": "The slide contrasts a traditional, lengthy development process with the accelerated VLx-enabled approach.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 85, "componentCount": 8, "textChars": 1167, "nDataPoints": 2, "notes": "The slide contrasts a traditional, lengthy development process with the accelerated VLx-enabled approach.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:17.578+00", "seconds": 10.814, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/18", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-18", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.46, "w": 0.206, "x": 0.213, "y": 0.058 }, "kind": "image", "text": "VLx device image", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0478990a-e3c5-4fe4-b22e-8c446d38fee2", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.445, "x": 0.055, "y": 0.535 }, "kind": "list", "text": "Transfect up to 200 billion cells in a fully closed, single-use system in less than 30 minutes; Achieve reproducible results, superior transfection efficiency, cell viability and protein expression; Bench-scale, modular equipment; Proprietary Flow Electroporation Technology; cGMP-compliant, closed, ISO-certified and CE-marked", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "528c7013-331b-47e5-abfa-07feccecc502", "parentComponentId": null }, { "bbox": { "h": 0.11, "w": 0.442, "x": 0.516, "y": 0.455 }, "kind": "list", "text": "The process begins with transiently expressing product using transfection early on in Discovery phase followed by establishing a stable cell line process (industry standard ~6+ months) in preclinical development and beyond; Stable cell line development process is lengthy, cumbersome, complex, and costly, and significantly contributes to time to IND filing", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "993ad5db-40ff-472e-8134-68b5e5f41825", "parentComponentId": null }, { "bbox": { "h": 0.11, "w": 0.442, "x": 0.516, "y": 0.735 }, "kind": "list", "text": "Expedites the production of the required amount of product (multi-gram quantify) to conduct in-vivo and in-vitro studies for IND filing in only ~4-6 weeks; This concept introduces a new “speed to product selection” strategy, enabling investment in stable cell line development only for promising/successful drug candidates", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a395db8-9384-4236-ab60-bf8136b1e702", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.175, "x": 0.516, "y": 0.685 }, "kind": "title", "text": "VLx-Enabled Approach", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0dee3e0b-4a22-44b3-8380-c6e2efdd7775", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.155, "x": 0.516, "y": 0.398 }, "kind": "title", "text": "Traditional Approach", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9315d10a-80a7-4706-8f77-4b5684b5418c", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.173, "x": 0.18, "y": 0.485 }, "kind": "title", "text": "VLx Platform Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b444f79f-7ef4-4072-871e-ec5a6af488eb", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.442, "x": 0.516, "y": 0.115 }, "kind": "title", "text": "Biotherapeutic Development: Monoclonal Antibodies, Recombinant Proteins and Vaccines", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8a94c7b-71af-499d-98d5-d905aeb2b82b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "9f64ba25-40fa-4429-bdd3-d2c01600b03f", "evidence": "Contrasts traditional lengthy process with accelerated VLx-enabled approach.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:10:17.578+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "before-after-framing" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 19, "type": "resolution", "title": "The slide uses a timeline-based comparison to highlight time savings (6+ months vs 1-2 months).", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 445, "nDataPoints": 2, "notes": "The slide uses a timeline-based comparison to highlight time savings (6+ months vs 1-2 months).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:14.006+00", "seconds": 6.999, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/19", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-19", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.32, "x": 0.64, "y": 0.72 }, "kind": "callout", "text": "* MaxCyte's VLx workflow enables production of multi-gram quantity of transiently-produced proteins in-house in only 4-6 weeks for use in pre-clinical and early-clinical studies.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "667f642f-7dae-4d36-b64a-1249254d844c", "parentComponentId": null }, { "bbox": { "h": 0.28, "w": 0.81, "x": 0.105, "y": 0.405 }, "kind": "chart", "text": "Comparison of development timelines: Traditional vs VLx-Enabled", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bee0633e-c3db-4d9c-bc73-4bfb79dd8b4d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.58, "x": 0.14, "y": 0.71 }, "kind": "diagram", "text": "VLx workflow steps: Seed Train, CCBE, Electroporation, Recovery, Bioproduction", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4926fe9d-c0c6-4c3c-8bdc-9fa72022d11c", "parentComponentId": null }, { "bbox": { "h": 0.28, "w": 0.68, "x": 0.16, "y": 0.13 }, "kind": "diagram", "text": "Biotherapeutic development process flow from target validation to Phase III", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "be5a9552-293f-4fe1-8afd-902aef256f4c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.56, "x": 0.038, "y": 0.045 }, "kind": "title", "text": "VLx-Enabled Approach for Biotherapeutic Development", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:14.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "51fdce30-289f-4032-86b6-8a9cd5657fe5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "0fe9f999-5131-4390-9966-5451d950b69d", "evidence": "Comparison of traditional vs new workflow timelines", "framework": null, "confidence": 0.95, "extraction": { "at": "2026-05-02 11:10:14.006+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "before-after-framing" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 20, "type": "evidence", "title": "The slide uses a process diagram to illustrate the workflow context for the company's technology.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 5, "textChars": 310, "nDataPoints": 2, "notes": "The slide uses a process diagram to illustrate the workflow context for the company's technology.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:10.026+00", "seconds": 2.963, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/20", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-20", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.22, "w": 0.88, "x": 0.06, "y": 0.18 }, "kind": "diagram", "text": "Cell therapy workflow: Prepare/Isolate, Concentrate, Culture, Cryopreserve, Thaw/Dose", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.026+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63b69631-2adc-4f9a-9829-6e6620c37c38", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.165, "x": 0.808, "y": 0.055 }, "kind": "image", "text": "MaxCyte", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.026+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "76be3feb-ed00-4c07-a1b9-4fe0d69962d5", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.03, "y": 0.435 }, "kind": "list", "text": "2023 Achievements: Five SPL partnerships, CFO appointment, ESG report, First therapy approval", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.026+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "01b5da71-6de9-4154-a0f8-fe78c8571330", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.45, "x": 0.51, "y": 0.435 }, "kind": "list", "text": "2024 YTD Achievements: CEO appointment, Lion TCR partnership, 24 total SPL partnerships", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.026+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "201b5896-f0b1-4ff8-af8f-4dc546a5c761", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "2023 Summary and 2024 YTD Achievements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:10.026+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "612a9a90-a89c-4d2b-9b65-da4f76ccf87d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a40501df-d9ed-4d9b-8ff5-4fdeeaa4dcfe", "evidence": "list/bullet: 2023 Achievements: Five SPL partnerships, CFO appointment, ESG report, First therapy approval", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:41:36.215617+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "ecd6a47c-e535-42c0-aa3d-8416a749baba", "evidence": "The slide presents a chronological summary of achievements across two distinct time periods.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:10:10.026+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [ { "to": 21, "from": 20, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "41f99638-2ab7-4bc5-8e96-09ca064b209b", "evidence": "The closing ask section implies that now is the right time to invest.", "position": 2, "objective": "Why is now the right time to invest in MaxCyte?", "confidence": 0.5, "extraction": { "at": "2026-07-16 22:42:20.409062+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "setup", "function": "state_next_steps", "rawType": "closing_ask", "block": null, "metadata": { "slideType": "closing_ask", "slideTypeCanon": { "name": "Closing ask", "slug": "closing_ask", "status": "active", "canonId": "019de52d-0aa4-750f-8aa1-8d622dd99f5c", "version": 1, "description": null }, "function": "state_next_steps", "functionCanon": { "name": "State next steps", "slug": "state_next_steps", "status": "active", "canonId": "019de52d-14ca-70ac-b534-971f458cdf29", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 3, "textChars": 415, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:10:09.905+00", "seconds": 2.709, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de076-b3a4-71cc-8183-985590ab9557/21", "deck": "/decks/019de076-b3a4-71cc-8183-985590ab9557", "deckAnchor": "/decks/019de076-b3a4-71cc-8183-985590ab9557#slide-21", "deckJson": "/decks/019de076-b3a4-71cc-8183-985590ab9557.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.7, "x": 0.15, "y": 0.65 }, "kind": "disclaimer", "text": "© 2023 MaxCyte, Inc. All rights reserved. MaxCyte®, MaxCyte ATx®, MaxCyte GT®, MaxCyte STx®, MaxCyte VLX®, Flow Transfection®, Flow Electroporation®, exPERT®, ATx®, STx® and GTx®, are registered trademarks of MaxCyte, Inc. MaxCyte GTx™, MaxCyte STx™, ExPERT ATx™, ExPERT GTx™, ExPERT STx™, ExPERT VLx™, ExPERT™, ATx™, GTx™, STx™, VLx™, and VLx™ are trademarks of MaxCyte, Inc.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.905+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79753c32-d7fd-441a-a94c-9cf9a22d969a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.16, "x": 0.42, "y": 0.55 }, "kind": "paragraph", "text": "ir@maxcyte.com", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.905+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5041a492-280c-498b-b3a2-21470eec8adb", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.32, "x": 0.34, "y": 0.26 }, "kind": "title", "text": "Thank you! Any questions?", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:10:09.905+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5beb30f6-6491-43a2-9164-c2c58229ed73", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Call to action", "slug": "call-to-action", "status": "active", "bestFor": null, "canonId": "019dd9e1-4bbb-702a-9ead-82daf188bb7c", "version": 1, "bodyDocId": null, "description": "Explicit prescription of what the audience should do next.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "70fabed5-30d3-4d95-9115-66db08d19ede", "evidence": "paragraph/paragraph: ir@maxcyte.com", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:41:36.339785+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Storytelling: the closing ask", "slug": "closing-ask", "status": "active", "bestFor": null, "canonId": "019df269-24e0-70ab-8dd9-983832c1c665", "version": 1, "bodyDocId": "019df269-24bc-7554-b88d-245127606b8d", "description": "The single most important slide in the deck — after the cover. The final", "familyLabel": "narrative-block", "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "372698dd-bc93-49c3-b5de-6b83ccc982ba", "evidence": "title/headline: Thank you! Any questions?", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:41:36.297743+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 21, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 21, "name": "The Ask", "beatId": "099b16d1-851c-4c93-9cff-a4e90fb2b444", "matchId": "3aa57115-5071-4e6b-864d-72dd0f7c5b17", "beatType": { "name": "The Ask", "slug": "sequoia-pitch-the-ask", "status": "active", "canonId": "019dd9b8-24f3-72bf-940a-74d06fd9396b", "version": 1, "description": null }, "evidence": "The ask is presented on page 21.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 21, "from": 20, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "41f99638-2ab7-4bc5-8e96-09ca064b209b", "evidence": "The closing ask section implies that now is the right time to invest.", "position": 2, "objective": "Why is now the right time to invest in MaxCyte?", "confidence": 0.5, "extraction": { "at": "2026-07-16 22:42:20.409062+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true } ], "arcBeats": [ { "from": 5, "to": 5, "label": "Problem", "description": "The problem statement is presented on page 5." }, { "from": 6, "to": 6, "label": "Solution", "description": "The solution is presented on page 6." }, { "from": 7, "to": 14, "label": "Traction", "description": "Traction is showcased from pages 7-14." }, { "from": 16, "to": 17, "label": "Business Model", "description": "The business model is explained on pages 16-17." }, { "from": 21, "to": 21, "label": "The Ask", "description": "The ask is presented on page 21." } ], "loops": [ { "from": 5, "to": 6, "label": "Cost Of Inaction", "description": "What are the consequences of not addressing cell engineering challenges?" }, { "from": 7, "to": 14, "label": "Quick Win Big Bet", "description": "What are the benefits of partnering with MaxCyte?" }, { "from": 20, "to": 21, "label": "Why Now", "description": "Why is now the right time to invest in MaxCyte?" } ] }